NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Harvard Case Solution & Analysis

NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Case Solution

Abstract:
NICE (National Institute for Health and Medical Quality) evaluates the expense efficiency of medicines for the procedure of multiple sclerosis (yearly expense per client $ 10,000-18,000) and does not license their usage within the UK National Health Service. A contract in between the makers and the Section of Health is arrived at on an ingenious danger discussing plan.

Pedagogical Goals:
Worth rates in the health care sector. Ramifications of worth rates for the primary stakeholders (clients, doctors, payers, makers). Ramifications of the taking in of expense efficiency requirements by health care purchasers for item advancement and worldwide release choices of pharmaceutical business.

This is just an excerpt. This case is about Marketing

published: 01 Jul 2006

NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK Case Solution Other Similar Case Solutions like

NICE or Nasty? Access and Reimbursement of Multiple Sclerosis Medicines in the UK

Share This